What is the recommended pembrolizumab dose and schedule for neoadjuvant chemotherapy in patients with triple‑negative breast cancer?

Pembrolizumab Dosing for Neoadjuvant Triple-Negative Breast Cancer

For stage II-III triple-negative breast cancer, pembrolizumab should be administered at 200 mg intravenously every 3 weeks throughout the neoadjuvant chemotherapy phase, followed by nine additional 3-week cycles in the adjuvant phase after surgery, regardless of pathological complete response status.

Dosing Regimen

The standard pembrolizumab dose is 200 mg IV every 3 weeks 1, 2. This dosing is supported by:

• ESMO Guidelines (2024): Explicitly state pembrolizumab should be given every 3 weeks throughout neoadjuvant treatment and for nine 3-week cycles during adjuvant phase 1
• NCCN Guidelines (2024): Recommend pembrolizumab with carboplatin + paclitaxel in the neoadjuvant phase, followed by pembrolizumab with cyclophosphamide + doxorubicin/epirubicin, then adjuvant pembrolizumab 2
• FDA Label: Confirms 200 mg every 3 weeks as the standard dose, with pharmacokinetic data showing no clinically significant exposure-response differences at this dosing 3

Treatment Algorithm

Neoadjuvant Phase (Pre-Surgery):

1. Cycles 1-4: Pembrolizumab 200 mg IV + paclitaxel + carboplatin every 3 weeks (12 weeks total)
2. Cycles 5-8: Pembrolizumab 200 mg IV + doxorubicin-cyclophosphamide OR epirubicin-cyclophosphamide every 3 weeks (12 weeks total)
3. Then proceed to definitive surgery

Adjuvant Phase (Post-Surgery):

• Nine additional cycles of pembrolizumab 200 mg IV every 3 weeks
• Critical: Continue adjuvant pembrolizumab regardless of whether pathological complete response was achieved 1
• Total pembrolizumab duration: Approximately 18 months (neoadjuvant + adjuvant combined)

Patient Selection Criteria

Pembrolizumab is indicated for:

• cT2-4 N0 OR any N-positive (stage II-III) TNBC 1
• cT1c-4 N0 or any N-positive disease where neoadjuvant treatment is preferred 1

Contraindications to consider:

• Risk factors for excessive ICI-associated immune toxicity 1
• Patients should be monitored very closely for immune-related adverse events throughout treatment 1

Evidence Strength

The KEYNOTE-522 trial provides Level I evidence demonstrating:

• Significantly higher pathological complete response rates (64.8% vs 51.2%, P<0.001) 4
• Improved event-free survival at 36 months (84.5% vs 76.8%, HR 0.63, P<0.001) 5
• Most importantly: Improved overall survival at 60 months (86.6% vs 81.7%, P=0.002) 6

Critical Caveats

Do NOT:

• Give ICI solely in the adjuvant setting without prior neoadjuvant ICI treatment 1
• Use alternative dosing schedules (e.g., 400 mg every 6 weeks) as this has not been validated in TNBC 3
• Discontinue adjuvant pembrolizumab based on pathological response—continue all nine adjuvant cycles 1

Special consideration: While low-dose pembrolizumab (50 mg every 6 weeks) is being investigated for cost-effectiveness 7, this remains experimental and should not be used outside clinical trials until proven equivalent.

Toxicity management: The most common grade ≥3 adverse events include neutropenia (73%), with immune-mediated adverse events occurring in approximately 30% of patients 8. Older patients (≥65 years) experience higher toxicity burden with increased treatment discontinuation rates 9.